Vanguard Global Advisers’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
Other funds holding STOK
LCM
Vanguard Global Advisers's STOK Position: Q3 2026 in Review
Vanguard Global Advisers reduced its Stoke Therapeutics (STOK) stake by 6% in Q3 2026, selling an estimated $48.4K and leaving 25,037 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #1967.
Vanguard Global Advisers first reported a position in STOK in Q1 2026 and has held it in 3 quarters since. The position peaked at $872K in Q2 2026. 185 funds tracked by Wall St. Rank hold STOK as of Q3 2026.
- Vanguard Global Advisers held 25,037 shares of Stoke Therapeutics worth $651K as of Q3 2026.
- Vanguard Global Advisers sold 1,602 Stoke Therapeutics shares in Q3 2026, an estimated $48.4K.
- Stoke Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1967 holding.
- Vanguard Global Advisers first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Stoke Therapeutics position peaked at $872K in Q2 2026.
- 185 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.